 In December 2015, Kite Pharma sold 4,168,750 shares of its common stock in a public offering at $69.00 per share, for gross proceeds of $287.6 million.In January 2017, Kite Pharma announced that it has partnered with Daiichi Sankyo Co Ltd to develop and commercialize its cancer treatment therapy in Japan, putting the U.S. company in line to receive up to $250 million in payments, of the $250 million, Kite said it would receive $50 million as upfront payment.Also in January, Kite Pharma announced that it had formed a joint venture with Fosun Pharmaceutical to develop and commercialize its cancer treatment in China.